Paradigm Biocapital Advisors LP Arcellx, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $3.1 Billion
- Q3 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,649,016 shares of ACLX stock, worth $418 Million. This represents 12.3% of its overall portfolio holdings.
Number of Shares
4,649,016
Previous 4,649,016
-0.0%
Holding current value
$418 Million
Previous $306 Million
24.68%
% of portfolio
12.3%
Previous 14.29%
Shares
11 transactions
Others Institutions Holding ACLX
# of Institutions
226Shares Held
51.4MCall Options Held
85.4KPut Options Held
113K-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.35MShares$572 Million0.32% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.91MShares$352 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$316 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.05MShares$274 Million15.63% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$273 Million4.28% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.94B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...